|This article needs additional citations for verification. (January 2010)|
||This article appears to be written like an advertisement. (November 2013)|
|Traded as||NYSE: ACT
S&P 500 Component
|Industry||Brand and generic pharmaceuticals, and pharmaceutical research and development.|
|Founded||Libertyville, Illinois, United States (Spring 1984)|
|Founder(s)||Allen Chao, Ph.D. and David Hsia, Ph.D.|
|Headquarters||Dublin, Ireland and Parsippany-Troy Hills, New Jersey, United States.|
|Number of locations||32 manufacturing facilities, 17 global R&D centers, a distribution center, and marketing/sales facilities worldwide.|
|Key people||Paul Bisaro, President & CEO|
|Products||Brand and generic pharmaceuticals|
|Revenue||US$ 5.9 billion(2012)|
|Operating income||US$ 320.8 million (2012)|
|Net income||US$ 98.3 million (2012)|
|Employees||17,000 employees worldwide (2013)|
Actavis plc ("NYSE: ACT) New York Stock Exchange is a global, integrated specialty pharmaceutical company focused on developing, manufacturing, and distributing generic, brand, and biosimilar products. The Company has global headquarters in Dublin, Ireland and administrative headquarters in Parsippany-Troy Hills, New Jersey, United States.
Actavis is the world's third-largest generics prescription drug manufacturer. Operating as Actavis Pharma, the Company develops, manufactures and markets generic, branded generic, legacy brands, and Over-the-Counter (OTC) products in more than 60 countries. The Company is ranked in the top 3 in 12 global markets, the top 5 in 16 global markets, and in the top 10 in 33 global markets. Actavis Pharma also develops and out-licenses generic pharmaceutical products outside the U.S. through its Medis third-party business, the world’s largest generic pharmaceutical out-licensing business. Medis has more than 300 customers globally, and offers a broad portfolio of more than 200 products.
Actavis Specialty Brands is the Company’s global branded specialty pharmaceutical business, which develops and markets a portfolio of products principally in the United States and Canada that are focused in the Urology and Women's Health therapeutic categories. Actavis Specialty Brands is committed to developing and marketing biosimilars products in Women’s Health, Oncology and other therapeutic categories, and currently has a portfolio of 5 biosimilar products in development. Actavis Global Operations has more than 30 manufacturing and distribution facilities around the world, with a capacity of approximately 40 billion units annually. Actavis Global Operations also includes Anda, Inc., the fourth-largest U.S. generic pharmaceutical product distributor in the United States.
The Company was founded in the spring of 1984, when, with funding from friends and family, colleagues Allen Chao, Ph.D. and David Hsia, Ph.D., began a small drug development enterprise. Just two months later, the founders established an initial product development and analytical laboratory with six employees (including both founders) in a leased space in Libertyville, Illinois.
By late Fall of the same year, the company moved to Southern California into an initial 2,000-square-foot (190 m2) leased facility in Corona, and the development and manufacturing of generic pharmaceuticals began. The Corona site became the Corporate headquarters for the rapidly expanding U.S. company.
In 2011, the company moved its corporate headquarters from Corona, California to Parsippany, New Jersey. The new LEED-certified[clarification needed] corporate headquarters at the Morris Corporate Center in Parsippany was formally dedicated on June 9, 2011.
Throughout its history, Actavis has expanded both organically and as the result of strategic acquisitions that brought broader product lines, enhanced drug delivery technologies, and ultimately branded pharmaceutical products to the company.
In 1993, Actavis, then Watson, announced its initial public offering (IPO) of shares of common stock. The company was initially listed on the NASDAQ under the ticker symbol WATS. The company moved to the New York Stock Exchange (NYSE) in 1997, and began trading under the symbol WPI.
In 2000, the company acquired Schein Pharmaceutical, Inc., an acquisition that more than doubled the company’s size. In that same year, the group reported revenues in excess of $1 billion. In 2005, again through acquisition, the company acquired a solid oral dosage manufacturing facility in Goa, India, and in early 2006 acquired Active Pharmaceutical Ingredient (API) manufacturing capacity in Mumbai, India. In the fall of 2006, it acquired Andrx Corporation, a Fort Lauderdale, FL–based pharmaceutical company, making it the third largest specialty pharmaceutical company based on total prescriptions dispensed.
In 2007, Dr. Allen Chao retired as President and Chief Executive Officer (CEO) and was succeeded by Paul M. Bisaro. The company’s international presence began with the acquisition of the Arrow Group in 2009, providing the company with commercial presence in more than 20 international markets. The combination of the two companies resulted in strong commercial positions in established markets such as the US, Canada, the UK, and France, and a sound platform for growth in solid markets such as Australia, New Zealand, Brazil, Scandinavia, and Germany.
As a result of the Arrow acquisition, the company also acquired the biopharmaceutical development organization Eden Biodesign in Liverpool, UK.
The company further strengthened its presence in Europe with the acquisition of Specifar Pharmaceuticals S.A. in May 2011. Based in Athens, Greece, Specifar is a generic pharmaceutical developer, manufacturer and marketer of products sold under its own and customer labels.
In December 2011, a collaboration agreement with Amgen was announced—to develop and commercialize oncology biosimilars, delivering on its stated objective to be a leader in the field of biosimilars.
In January 2012, the Company acquired Ascent Pharmahealth Ltd, the Australia and Southeast Asia generic pharmaceutical business of Strides Acrolab Ltd. As a result of the acquisition Watson became the fifth largest generic pharmaceutical company in Australia based on revenue, and the largest generics company in Singapore, with an established commercial base in Malaysia, Hong Kong, Vietnam, and Thailand.
In November 2012, Watson acquired the Switzerland based, global generics Company Actavis Group for EUR4.25 billion, creating the world’s third largest generics company, with a leading position in key established commercial markets including the U.S., UK, Nordics, Canada, Australia, and emerging markets in Central and Eastern Europe, and Russia. Following the acquisition, Watson adopted Actavis's name for its global operations.
Actavis’s Specialty Brands division was strengthened in January 2013 with the acquisition of Belgian based Uteron Pharma SA, which specializes in Women’s health products.
On October 1, 2013. Actavis announced that it had completed its acquisition of Warner Chilcott plc in a stock-for-stock transaction valued at approximately $8.5 billion. The combination creates a leading global specialty pharmaceutical company with approximately $11 billion in anticipated combined annual 2013 revenue, and the third-largest U.S. specialty pharmaceutical company with approximately $3 billion in annual revenue focused on the core therapeutic categories of Women’s Health, Urology, Gastroenterology and Dermatology.
Locations and facilities
- Global headquarters
The company's U.S. and global headquarters are located in Dublin, Ireland. Administrative headquarters are located in Parsippany, New Jersey, USA.
- Sales and marketing offices
Actavis holds a leading position in key established commercial markets including the U.S., UK, Nordics, Canada, Australia and the Pacific Rim, and emerging markets in Central and Eastern Europe and Russia.
Sales and marketing offices are located in five continents:
- The Americas
- The US, Canada and Brazil.
- Austria, the Balkans, the Baltics, Belgium, Bulgaria, the CIS, the Czech Republic, France, Germany, Greece, Hungary, Ireland, Italy, the Nordic region, Malta, the Netherlands, Poland, Portugal, Romania, Russia, Serbia, Slovenia, Slovakia, Spain, Switzerland, Turkey, Ukraine, and the United Kingdom.
- Middle East and Africa
- United Arab Emirates and South-Africa.
- Australia, China, Hong Kong, Indonesia, Japan, New Zealand, Malaysia, Singapore, Thailand and Vietnam.
- Third-party sales
- Germany, Greece, Iceland and the United Kingdom.
- Manufacturing facilities
The Company has 32 manufacturing facilities in five continents providing the company with a core leadership position in modified release products, solid oral dosages, transdermals, semi-solids, liquids and injectables.
The Company’s manufacturing facilities are located in Brazil, Bulgaria, Canada, China, Germany, Greece, Iceland, India, Ireland, Indonesia, Malta, Romania, Russian, Singapore, Serbia, the United Kingdom, Puerto Rico and the US.
- Research & Development facilities
Actavis has 17 global R&D facilities focusing on the development of modified release products, solid oral dosages, transdermals, semi-solids, liquids and injectables around the world.
The Company’s R&D facilities are located in Bulgaria, Greece, Iceland, India, Indonesia, Ireland, Malta, Romania, the United Kingdom and the US.
Specialty pharmaceuticals: India, Romania, UK, the US. Branded pharmaceuticals: Salt Lake City, New Jersey, US, Liege, Belgium and Liverpool, UK (biologics).
- "Actavis to buy Forest for $25 billion; windfall for investor Icahn". Reuters. 18 Feb 2014. Retrieved 20 Feb 2014.